

# Olivia Pagani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2269657/publications.pdf>

Version: 2024-02-01

74  
papers

5,457  
citations

117571

34  
h-index

82499

72  
g-index

75  
all docs

75  
docs citations

75  
times ranked

6209  
citing authors

#	ARTICLE	IF	CITATIONS
1	Breast cancer in the oldest old (≥ 89 years): Tumor characteristics, treatment choices, clinical outcomes and literature review. <i>European Journal of Surgical Oncology</i> , 2021, 47, 796-803.	0.5	4
2	Managing Menopausal Symptoms in Young Women With Breast Cancer: When Medicine Is Not All. The Take Care Project. <i>Clinical Breast Cancer</i> , 2021, 21, e547-e560.	1.1	3
3	Breast Cancer Management During the COVID-19 Pandemic: The Senologic International Society Survey. <i>The Journal of Breast Health</i> , 2021, 17, 188-196.	0.4	9
4	A Breast Cancer Smartphone App to Navigate the Breast Cancer Journey: Mixed Methods Study. <i>JMIR Formative Research</i> , 2021, 5, e28668.	0.7	11
5	Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 3293-3305.	0.8	70
6	Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. <i>Breast</i> , 2021, 59, 327-338.	0.9	31
7	Genetic Literacy and Communication of Genetic Information in Families Concerned with Hereditary Breast and Ovarian Cancer: A Cross-Study Comparison in Two Countries and within a Timeframe of More Than 10 Years. <i>Cancers</i> , 2021, 13, 6254.	1.7	5
8	Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. <i>Journal of Clinical Oncology</i> , 2020, 38, 1293-1303.	0.8	93
9	The impact of depression on adherence to organized and opportunistic breast cancer screening. <i>European Journal of Cancer Prevention</i> , 2020, 29, 53-59.	0.6	3
10	Physicians communicating with women at genetic risk of breast and ovarian cancer: Are we in the middle of the ford between contradictory messages and unshared decision making?. <i>PLoS ONE</i> , 2020, 15, e0240054.	1.1	6
11	Estimation of historical control rate for a single arm de-escalation study – Application to the POSITIVE trial. <i>Breast</i> , 2020, 53, 1-7.	0.9	13
12	Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 347-359.	1.1	19
13	Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic. <i>Breast</i> , 2020, 52, 8-16.	0.9	188
14	Granular cell tumor of the breast: a multidisciplinary challenge. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 144, 102828.	2.0	14
15	Luminal Metastatic Breast Cancer. <i>Breast Care</i> , 2019, 14, 99-101.	0.8	1
16	Trends in axillary lymph node dissection for early-stage breast cancer in Europe: Impact of evidence on practice. <i>Breast</i> , 2019, 45, 89-96.	0.9	25
17	Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. <i>British Journal of Cancer</i> , 2019, 120, 959-967.	2.9	5
18	Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows. <i>Journal of Clinical Oncology</i> , 2019, 37, 862-866.	0.8	17

#	ARTICLE	IF	CITATIONS
19	Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients. <i>Reproductive BioMedicine Online</i> , 2019, 38, 835-844.	1.1	29
20	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 127-138.	5.1	91
21	Challenges and Opportunities for Cancer Predisposition Cascade Screening for Hereditary Breast and Ovarian Cancer and Lynch Syndrome in Switzerland: Findings from an International Workshop. <i>Public Health Genomics</i> , 2018, 21, 121-132.	0.6	20
22	Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1385-1393.	5.1	342
23	The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. <i>Breast</i> , 2018, 42, 41-49.	0.9	75
24	Should age impact breast cancer management in young women? Fine tuning of treatment guidelines. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877692.	1.4	27
25	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 122-137.	13.9	448
26	Can we make a portrait of women with inoperable locally advanced breast cancer?. <i>Breast</i> , 2017, 33, 83-90.	0.9	8
27	ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). <i>Breast</i> , 2017, 35, 203-217.	0.9	203
28	Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients. <i>Endocrine Connections</i> , 2017, 6, 549-556.	0.8	11
29	Oncology Physicians' Perspectives on Practices and Barriers to Fertility Preservation and the Feasibility of a Prospective Study of Pregnancy After Breast Cancer. <i>Journal of Adolescent and Young Adult Oncology</i> , 2017, 6, 429-434.	0.7	26
30	Is it time to address survivorship in advanced breast cancer? A review article. <i>Breast</i> , 2017, 31, 167-172.	0.9	31
31	Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 3113-3122.	0.8	101
32	Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol. <i>JMIR Research Protocols</i> , 2017, 6, e184.	0.5	30
33	Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Early Breast Cancer: TEXT and SOFT Trials. <i>Journal of Clinical Oncology</i> , 2016, 34, 2221-2231.	0.8	148
34	Are SOFT and TEXT results practice changing and how?. <i>Breast</i> , 2016, 27, 122-125.	0.9	14
35	Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 393-410.	1.1	58
36	Second international consensus guidelines for breast cancer in young women (BCY2). <i>Breast</i> , 2016, 26, 87-99.	0.9	142

#	ARTICLE	IF	CITATIONS
37	The Modern Landscape of Endocrine Therapy for Premenopausal Women with Breast Cancer. <i>Breast Care</i> , 2015, 10, 312-315.	0.8	10
38	Clear Cell Carcinoma of the Breast: A Rare Breast Cancer Subtype - Case Report and Literature Review. <i>Case Reports in Oncology</i> , 2015, 8, 472-477.	0.3	9
39	A rare avascular osteonecrosis of the knee related to biphosphonate treatment in a patient with metastatic breast cancer. <i>Breast Disease</i> , 2015, 35, 203-206.	0.4	2
40	Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. <i>Lancet Oncology</i> , The, 2015, 16, 848-858.	5.1	145
41	Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?. <i>Breast</i> , 2015, 24, 201-207.	0.9	97
42	CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 373-384.	1.1	26
43	Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 275-286.	1.1	37
44	ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 543-555.	1.1	16
45	Challenges in managing genetic cancer risk: a long-term qualitative study of unaffected women carrying BRCA1/BRCA2 mutations. <i>Genetics in Medicine</i> , 2015, 17, 726-732.	1.1	17
46	Estramustine phosphate sodium in heavily pretreated patients with metastatic breast cancer: a retrospective consecutive case series. <i>International Journal of Clinical Oncology</i> , 2015, 20, 90-94.	1.0	2
47	Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 1357-1359.	13.9	22
48	First international consensus guidelines for breast cancer in young women (BCY1). <i>Breast</i> , 2014, 23, 209-220.	0.9	135
49	Oligometastatic Breast Cancer: A Shift from Palliative to Potentially Curative Treatment?. <i>Breast Care</i> , 2014, 9, 7-14.	0.8	65
50	Time for more optimism in metastatic breast cancer?. <i>Cancer Treatment Reviews</i> , 2014, 40, 220-228.	3.4	59
51	Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 107-118.	13.9	621
52	Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials. <i>Breast</i> , 2013, 22, 1094-1100.	0.9	73
53	Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-93 and 14-93. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 455-459.	1.1	19
54	Supportive care during treatment for breast cancer: Resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. <i>Breast</i> , 2013, 22, 593-605.	0.9	60

#	ARTICLE	IF	CITATIONS
55	International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)â€™MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. <i>Breast</i> , 2013, 22, 203-210.	0.9	77
56	Practical aspects of genetic counseling in breast cancer: Lights and shadows. <i>Breast</i> , 2013, 22, 375-382.	0.9	30
57	Differential expression of testin and survivin in breast cancer subtypes. <i>Oncology Reports</i> , 2013, 30, 824-832.	1.2	12
58	Pregnancy after Breast Cancer: Myths and Facts. <i>Breast Care</i> , 2012, 7, 210-214.	0.8	23
59	CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial. <i>Journal of the National Cancer Institute</i> , 2012, 104, 441-451.	3.0	316
60	Fertility after breast cancer. <i>Maturitas</i> , 2012, 73, 191-196.	1.0	38
61	Can we further improve the outcome of ER+ MBC?. <i>Breast</i> , 2011, 20, S21-S22.	0.9	0
62	Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 221-226.	1.1	55
63	Pregnancy after breast cancer: if you wish, maâ€™am. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 309-317.	1.1	81
64	Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. <i>Breast</i> , 2010, 19, 388-395.	0.9	69
65	Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 3422-3428.	0.8	228
66	International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?. <i>Journal of the National Cancer Institute</i> , 2010, 102, 456-463.	3.0	325
67	International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1174-1181.	3.0	202
68	Adjuvant endocrine therapy for perimenopausal women with early breast cancer. <i>Breast</i> , 2009, 18, 2-7.	0.9	14
69	Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12â€™93. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 491-500.	1.1	37
70	Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 319-324.	1.1	49
71	Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group. <i>Supportive Care in Cancer</i> , 2008, 16, 67-74.	1.0	11
72	Treatment of Premenopausal Women with Early Breast Cancer. <i>Drugs</i> , 2007, 67, 1393-1401.	4.9	11

#	ARTICLE	IF	CITATIONS
73	Site of Primary Tumor Has a Prognostic Role in Operable Breast Cancer: The International Breast Cancer Study Group Experience. <i>Journal of Clinical Oncology</i> , 2005, 23, 1390-1400.	0.8	74
74	Anastrozole (â€ˆArimidexâ€™™) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or â€ˆArimidexâ€™™ Randomized Group Efficacy and Tolerability) trial. <i>Breast Cancer Research and Treatment</i> , 2004, 85, 247-254.	1.1	69